DOCSLIB.ORG

Psychotropic Medications

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Psychotropic Medications PSYCHOTROPIC MEDICATIONS Schizophrenia Depression Anxiety Disorders* Typical antipsychotics: Tricylics: Ativan (lorazepam) Haldol (haloperidol) Anafranil (clomipramine) BuSpar (buspirone) Haldol Decanoate Injection Asendin (amoxapine) Klonopin (clonazepam) Loxitane (loxapine) Elavil (amitriptyline) Librium (chlordiazepoxide) Mellaril (thiordazine) Norpramin (desipramine) Serax (oxazepam) Moban (molindone) Pamelor (nortriptyline) Tenormin (atenolol) Navane (thiothixene) Sinequan (doxepin) Tranxene (clorazepate) Orap (pimozide) Surmontil (trimipramine) Valium (diazepam) Prolixin (fluphenazine) Tofranil (imipramine) Vistaril (hydroxyzine) Prolixin Decanoate Injection Vivactil (protriptyline) Xanax (alprazolam) Serentil (mesoridazine) Stelazine (trifluoperazine) SSRI's: Panic Disorder* Thorazine (chlorpromazine) Celexa (citalopram) Inderal (propranolol) Trilafon (perphenazine) Lexapro (escitalopram) Klonopin (clonazepam) Luvox (fluvoxamine) Paxil (paroxetine) Atypical antipsychotics: Paxil (paroxetine) Prozac (fluoxetine) Abilify (aripiprazole) Prozac (fluoxetine) Xanax (alprazolam) Clozaril (clozapine) Zoloft (sertraline) Zoloft (sertraline) Geodon (ziprasidone) *Antidepressants, especially SSRIs, Invega (paliperidone) MAOI's: are also used to treat anxiety and panic. Risperdal (risperidone) Nardil (phenelzine) Risperdal Consta Injection Parnate (tranylcypromine) CNS Stimulants/ADHD Agents Seroquel (quetiapine) EmSam patch (selegiline) Adderall (amphetamine and Zyprexa (olanzapine) dextroamphetamine) Others: Concerta (methylphenidate) Anticonvulsants/Mood Stabilizers Cymbalta (duloxetine) Focalin (dexmethylphenidate) Carbatrol (Carbamazepine) Desyrel (trazodone) Dexedrine (dextroamphetamine) Depakene (valproic acid) Effexor (venlafaxine) Ritalin (methylphenidate) Depakote (divalproex sodium) Remeron (mirtazapine) Strattera (atomoxetine) Dilantin (phenytoin) Serzone (nefazodone) Vyvanse (lisdexamfetamine) Eskalith, Lithobid, Lithonate, Wellbutrin (bupropion) Lithotabs (lithium carbonate) Miscellaneous CNS Agents Gabatril (tiagabine) Anti-Obsessive Agents Antabuse (disulfiram) Keppra (levetiracetam) Anafranil (clomipramine) Campral (acamprosate) Lamictal (lamotrigine) Celexa (citalopram) Chantix (varenicline) Lyrica (pregabalin) Luvox (fluvoxamine) Methadose (methadone) Neurontin (gabapentin) Paxil (paroxetine) Narcan (naloxone) Tegretol (carbamazepine) Prozac (fluoxetine) Revia (naltrexone) Trileptal (oxcarbamazepine) Zoloft (sertraline) Suboxone (buprenorphine/naloxone) Topamax (topiramate) Subutex (buprenorphine) Listed above are the brand names, followed by the generic in parentheses of commonly prescribed psychotropic medications. A second chart on the back of this sheet provides cross-referencing by generic name. As with all questions about medication, consult with your physician or pharmacist for any specific questions about dosage, drug interactions, or side effects. .
Load more

Recommended publications
  • NH Healthy Families Preferred Drug List (PDL) Is the List of Covered Drugs
    Pharmacy Program NH Healthy Families is committed to providing appropriate, high quality, and cost effective drug therapy to all NH Healthy Families members. NH Healthy Families works with providers and pharmacists to ensure that medications used to treat a variety of conditions and diseases are covered. NH Healthy Families covers prescription medications and certain over-the-counter (OTC) medications when ordered by a practitioner. The pharmacy program does not cover all medications. Some medications require prior authorization (PA) or have limitations on age, dosage, and maximum quantities. Preferred Drug List The NH Healthy Families Preferred Drug List (PDL) is the list of covered drugs. The PDL applies to drugs members can receive at retail pharmacies. The NH Healthy Families PDL is continually evaluated by the NH Healthy Families Pharmacy and Therapeutics (P&T) Committee to promote the appropriate and cost- effective use of medications. The Committee is composed of the NH Healthy Families Medical Director, NH Healthy Families Pharmacy Director, and several New Hampshire physicians, pharmacists, and other healthcare professionals. Pharmacy Benefit Manager NH Healthy Families works with Envolve Pharmacy Solutions to process pharmacy claims for prescribed drugs. Some drugs on the NH Healthy Families PDL may require PA, and Envolve Pharmacy Solutions is responsible for administering this process. Envolve Pharmacy Solutions is our Pharmacy Benefit Manager (PBM). Specialty Drugs NH Healthy Families contracts with a number of specialty pharmacies, such as AcariaHealth Specialty Pharmacy, to ensure members have adequate access to the specialty drugs they require. Specialty drugs, such as biopharmaceuticals and injectables, may require PA to be approved for payment by NH Healthy Families.
    [Show full text]
  • Minimum Laboratory Monitoring for Psychotropic Medications
    Minimum Laboratory Monitoring For Psychotropic Medications ANTIPSYCHOTIC MEDICATIONS GENERIC BRAND GENERIC BRAND Aripiprazole Abilify, Abilify Olanzapine Zyprexa, Zyprexa Zydis Maintena, Aristada Asenapine Saphris Paliperidone Invega, Invega Sustenna, Invega Trinza Brexpiprazole Rexulti Perphenazine Trilafon Cariprazine Vraylar Pimozide Orap Chlorpromazine Thorazine Quetiapine Seroquel, Seroquel XR Clozapine Clozaril, Fazaclo Risperidone Risperdal, Risperdal Consta, Risperdal M Tabs Fluphenazine, Fluphenazine D Prolixin, Prolixin D Thioridazine Mellaril Haloperidol, Haloperidol D Haldol, Haldol D Thiothixene Navane Iloperidone Fanapt Trifluoperazine Stelazine Loxapine Loxitane Ziprasidone Geodon Lurasidone Latuda MONITORING ANTIPSYCHOTIC FREQUENCY OF MONITORING AIMS (Abnormal Involuntary Movement Scale) On initiation of any antipsychotic medication and at least every six months thereafter, or more frequently as clinically indicated. ABDOMINAL GIRTH (>18 years old) For individuals at least 18 years old, on initiation of any medication and at least every six months thereafter, or more frequently as clinically indicated. WEIGHT & BODY MASS INDEX (BMI) On initiation of any medication and at least every six months thereafter, or more frequently as clinically indicated. HEART RATE & BLOOD PRESSSURE On initiation of any medication and at least every six months thereafter, or more frequently as clinically indicated. COMPREHENSIVE METABOLIC PANEL (CMP), On initiation of any medication affecting this parameter and at least annually LIPIDS, FASTING
    [Show full text]
  • Schizophrenia Care Guide
    August 2015 CCHCS/DHCS Care Guide: Schizophrenia SUMMARY DECISION SUPPORT PATIENT EDUCATION/SELF MANAGEMENT GOALS ALERTS Minimize frequency and severity of psychotic episodes Suicidal ideation or gestures Encourage medication adherence Abnormal movements Manage medication side effects Delusions Monitor as clinically appropriate Neuroleptic Malignant Syndrome Danger to self or others DIAGNOSTIC CRITERIA/EVALUATION (PER DSM V) 1. Rule out delirium or other medical illnesses mimicking schizophrenia (see page 5), medications or drugs of abuse causing psychosis (see page 6), other mental illness causes of psychosis, e.g., Bipolar Mania or Depression, Major Depression, PTSD, borderline personality disorder (see page 4). Ideas in patients (even odd ideas) that we disagree with can be learned and are therefore not necessarily signs of schizophrenia. Schizophrenia is a world-wide phenomenon that can occur in cultures with widely differing ideas. 2. Diagnosis is made based on the following: (Criteria A and B must be met) A. Two of the following symptoms/signs must be present over much of at least one month (unless treated), with a significant impact on social or occupational functioning, over at least a 6-month period of time: Delusions, Hallucinations, Disorganized Speech, Negative symptoms (social withdrawal, poverty of thought, etc.), severely disorganized or catatonic behavior. B. At least one of the symptoms/signs should be Delusions, Hallucinations, or Disorganized Speech. TREATMENT OPTIONS MEDICATIONS Informed consent for psychotropic
    [Show full text]
  • Medicines That Affect Fluid Balance in the Body
    the bulk of stools by getting them to retain liquid, which encourages the Medicines that affect fluid bowels to push them out. balance in the body Osmotic laxatives e.g. Lactulose, Macrogol - these soften stools by increasing the amount of water released into the bowels, making them easier to pass. Older people are at higher risk of dehydration due to body changes in the ageing process. The risk of dehydration can be increased further when Stimulant laxatives e.g. Senna, Bisacodyl - these stimulate the bowels elderly patients are prescribed medicines for chronic conditions due to old speeding up bowel movements and so less water is absorbed from the age. stool as it passes through the bowels. Some medicines can affect fluid balance in the body and this may result in more water being lost through the kidneys as urine. Stool softener laxatives e.g. Docusate - These can cause more water to The medicines that can increase risk of dehydration are be reabsorbed from the bowel, making the stools softer. listed below. ANTACIDS Antacids are also known to cause dehydration because of the moisture DIURETICS they require when being absorbed by your body. Drinking plenty of water Diuretics are sometimes called 'water tablets' because they can cause you can reduce the dry mouth, stomach cramps and dry skin that is sometimes to pass more urine than usual. They work on the kidneys by increasing the associated with antacids. amount of salt and water that comes out through the urine. Diuretics are often prescribed for heart failure patients and sometimes for patients with The major side effect of antacids containing magnesium is diarrhoea and high blood pressure.
    [Show full text]
  • Management of Side Effects of Antipsychotics
    Management of side effects of antipsychotics Oliver Freudenreich, MD, FACLP Co-Director, MGH Schizophrenia Program www.mghcme.org Disclosures I have the following relevant financial relationship with a commercial interest to disclose (recipient SELF; content SCHIZOPHRENIA): • Alkermes – Consultant honoraria (Advisory Board) • Avanir – Research grant (to institution) • Janssen – Research grant (to institution), consultant honoraria (Advisory Board) • Neurocrine – Consultant honoraria (Advisory Board) • Novartis – Consultant honoraria • Otsuka – Research grant (to institution) • Roche – Consultant honoraria • Saladax – Research grant (to institution) • Elsevier – Honoraria (medical editing) • Global Medical Education – Honoraria (CME speaker and content developer) • Medscape – Honoraria (CME speaker) • Wolters-Kluwer – Royalties (content developer) • UpToDate – Royalties, honoraria (content developer and editor) • American Psychiatric Association – Consultant honoraria (SMI Adviser) www.mghcme.org Outline • Antipsychotic side effect summary • Critical side effect management – NMS – Cardiac side effects – Gastrointestinal side effects – Clozapine black box warnings • Routine side effect management – Metabolic side effects – Motor side effects – Prolactin elevation • The man-in-the-arena algorithm www.mghcme.org Receptor profile and side effects • Alpha-1 – Hypotension: slow titration • Dopamine-2 – Dystonia: prophylactic anticholinergic – Akathisia, parkinsonism, tardive dyskinesia – Hyperprolactinemia • Histamine-1 – Sedation – Weight gain
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Adverse Reactions to Hallucinogenic Drugs. 1Rnstttutton National Test
    DOCUMENT RESUME ED 034 696 SE 007 743 AUTROP Meyer, Roger E. , Fd. TITLE Adverse Reactions to Hallucinogenic Drugs. 1rNSTTTUTTON National Test. of Mental Health (DHEW), Bethesda, Md. PUB DATP Sep 67 NOTE 118p.; Conference held at the National Institute of Mental Health, Chevy Chase, Maryland, September 29, 1967 AVATLABLE FROM Superintendent of Documents, Government Printing Office, Washington, D. C. 20402 ($1.25). FDPS PRICE FDPS Price MFc0.50 HC Not Available from EDRS. DESCPTPTOPS Conference Reports, *Drug Abuse, Health Education, *Lysergic Acid Diethylamide, *Medical Research, *Mental Health IDENTIFIEPS Hallucinogenic Drugs ABSTPACT This reports a conference of psychologists, psychiatrists, geneticists and others concerned with the biological and psychological effects of lysergic acid diethylamide and other hallucinogenic drugs. Clinical data are presented on adverse drug reactions. The difficulty of determining the causes of adverse reactions is discussed, as are different methods of therapy. Data are also presented on the psychological and physiolcgical effects of L.S.D. given as a treatment under controlled medical conditions. Possible genetic effects of L.S.D. and other drugs are discussed on the basis of data from laboratory animals and humans. Also discussed are needs for futher research. The necessity to aviod scare techniques in disseminating information about drugs is emphasized. An aprentlix includes seven background papers reprinted from professional journals, and a bibliography of current articles on the possible genetic effects of drugs. (EB) National Clearinghouse for Mental Health Information VA-w. Alb alb !bAm I.S. MOMS Of NAM MON tMAN IONE Of NMI 105 NUNN NU IN WINES UAWAS RCM NIN 01 NUN N ONMININI 01011110 0.
    [Show full text]
  • Appendix 13C: Clinical Evidence Study Characteristics Tables
    APPENDIX 13C: CLINICAL EVIDENCE STUDY CHARACTERISTICS TABLES: PHARMACOLOGICAL INTERVENTIONS Abbreviations ............................................................................................................ 3 APPENDIX 13C (I): INCLUDED STUDIES FOR INITIAL TREATMENT WITH ANTIPSYCHOTIC MEDICATION .................................. 4 ARANGO2009 .................................................................................................................................. 4 BERGER2008 .................................................................................................................................... 6 LIEBERMAN2003 ............................................................................................................................ 8 MCEVOY2007 ................................................................................................................................ 10 ROBINSON2006 ............................................................................................................................. 12 SCHOOLER2005 ............................................................................................................................ 14 SIKICH2008 .................................................................................................................................... 16 SWADI2010..................................................................................................................................... 19 VANBRUGGEN2003 ....................................................................................................................
    [Show full text]
  • Current P SYCHIATRY
    Current p SYCHIATRY N ew Investigators Tips to manage and prevent discontinuation syndromes Informed tapering can protect patients when you stop a medication Sriram Ramaswamy, MD Shruti Malik, MBBS, MHSA Vijay Dewan, MD Instructor, department of psychiatry Foreign medical graduate Assistant professor Creighton University Department of psychiatry Omaha, NE University of Nebraska Medical Center Omaha, NE bruptly stopping common psychotropics New insights on psychotropic A —particularly antidepressants, benzodi- drug safety and side effects azepines, or atypical antipsychotics—can trigger a discontinuation syndrome, with: This paper was among those entered in the 2005 • rebound or relapse of original symptoms Promising New Investigators competition sponsored • uncomfortable new physical and psycho- by the Neuroleptic Malignant Syndrome Information Service (NMSIS). The theme of this year’s competition logical symptoms was “New insights on psychotropic drug safety and • physiologic withdrawal at times. side effects.” To increase health professionals’ awareness of URRENT SYCHIATRY 1 C P is honored to publish this peer- the risk of these adverse effects, this article reviewed, evidence-based article on a clinically describes discontinuation syndromes associated important topic for practicing psychiatrists. with various psychotropics and offers strategies to NMSIS is dedicated to reducing morbidity and anticipate, recognize, and manage them. mortality of NMS by improving medical and psychiatric care of patients with heat-related disorders; providing
    [Show full text]
  • Clinical Review, Adverse Events
    Clinical Review, Adverse Events Drug: Carbamazepine NDA: 16-608, Tegretol 20-712, Carbatrol 21-710, Equetro Adverse Event: Stevens-Johnson Syndrome Reviewer: Ronald Farkas, MD, PhD Medical Reviewer, DNP, ODE I 1. Executive Summary 1.1 Background Carbamazepine (CBZ) is an anticonvulsant with FDA-approved indications in epilepsy, bipolar disorder and neuropathic pain. CBZ is associated with Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), closely related serious cutaneous adverse drug reactions that can be permanently disabling or fatal. Other anticonvulsants, including phenytoin, phenobarbital, and lamotrigine are also associated with SJS/TEN, as are members of a variety of other drug classes, including nonsteriodal anti-inflammatory drugs and sulfa drugs. The incidence of CBZ-associated SJS/TEN has been considered “extremely rare,” as noted in current U.S. drug labeling. However, recent publications and postmarketing data suggest that CBZ- associated SJS/TEN occurs at a much higher rate in some Asian populations, about 2.5 cases per 1,000 new exposures, and that most of this increased risk is in individuals carrying a specific human leukocyte antigen (HLA) allele, HLA-B*1502. This HLA-B allele is present in about 5- to 20% of many, but not all, Asian populations, and is also present in about 2- to 4% of South Asians/Indians. The allele is also present at a lower frequency, < 1%, in several other ethnic groups around the world (although likely due to distant Asian ancestry). About 10% of U.S. Asians carry HLA-B*1502. HLA-B*1502 is generally not present in the U.S.
    [Show full text]
  • Hydroxyzine Prescribing Information
    Hydroxyzine Hydroxyzine Hydrochloride Hydrochloride Injection, USP Injection, USP (For Intramuscular Use Only) (For Intramuscular Use Only) Rx Only Rx Only DESCRIPTION: Hydroxyzine hydrochloride has the chemical name of (±)-2-[2-[4-( p-Chloro- a- phenylbenzyl)-1-piperazinyl]ethoxy]ethanol dihydrochloride and occurs as a white, odorless powder which is very soluble in water. It has the following structural formula: Molecular Formula: C 21 H27 ClN 2O2•2HCl Molecular Weight: 447.83 Hydroxyzine Hydrochloride Injection, USP is a sterile aqueous solution intended for intramuscular administration. Each mL contains: Hydroxyzine HCl 25 mg or 50 mg, Benzyl Alcohol 0.9%, and Water for Injection q.s. pH adjusted with Sodium Hydroxide and/or Hydrochloric Acid. CLINICAL PHARMACOLOGY: Hydroxyzine hydrochloride is unrelated chemically to phenothiazine, reserpine, and meprobamate. Hydroxyzine has demonstrated its clinical effectiveness in the chemotherapeutic aspect of the total management of neuroses and emotional disturbances manifested by anxiety, tension, agitation, apprehension or confusion. Hydroxyzine has been shown clinically to be a rapid-acting true ataraxic with a wide margin of safety. It induces a calming effect in anxious, tense, psychoneurotic adults and also in anxious, hyperkinetic children without impairing mental alertness. It is not a cortical depressant, but its action may be due to a suppression of activity in certain key regions of the subcortical area of the central nervous system. Primary skeletal muscle relaxation has been demonstrated experimentally. Hydroxyzine has been shown experimentally to have antispasmodic properties, apparently mediated through interference with the mechanism that responds to spasmogenic agents such as serotonin, acetylcholine, and histamine. Antihistaminic effects have been demonstrated experimentally and confirmed clinically.
    [Show full text]
  • Psychotropic Medication Concerns When Treating Individuals with Developmental Disabilities
    Tuesday, 2:30 – 4:00, C2 Psychotropic Medication Concerns when Treating Individuals with Developmental Disabilities Richard Berchou 248-613-6716 [email protected] Objective: Identify effective methods for the practical application of concepts related to improving the delivery of services for persons with developmental disabilities Notes: Medication Assistance On-Line Resources OBTAINING MEDICATION: • Needy Meds o Needymeds.com • Partnership for Prescriptions Assistance o Pparx.org • Patient Assistance Program Center o Rxassist.org • Insurance coverage & Prior authorization forms for most drug plans o Covermymeds.com REMINDERS TO TAKE MEDICATION: • Medication reminder by Email, Phone call, or Text message o Sugaredspoon.com ANSWER MOST QUESTIONS ABOUT MEDICATIONS: • Univ. of Michigan/West Virginia Schools of Pharmacy o Justaskblue.com • Interactions between medications, over-the-counter (OTC) products and some foods; also has a pictorial Pill Identifier: May input an entire list of medications o Drugs.com OTHER TRUSTED SITES: • Patient friendly information about disease and diagnoses o Mayoclinic.com, familydoctor.org • Package inserts, boxed warnings, “Dear Doctor” letters (can sign up to receive e- mail alerts) o Dailymed.nlm.nih.gov • Communications about drug safety o www.Fda.gov/cder/drug/drugsafety/drugindex.htm • Purchasing medications on-line o Pharnacychecker.com Updated 2013 Psychotropic Medication for Persons with Developmental Disabilities April 23, 2013 Richard Berchou, Pharm. D. Assoc. Clinical Prof., Dept. Psychiatry & Behavioral
    [Show full text]